Employees Want to Know: How Will The Pfizer-Allergan Merger Impact Me?
This article was originally published in Scrip
Will I lose my job? Will the research I've worked on for years or the strategy I've spent months executing lose funding? How will my team be integrated into Pfizer PLC and when that happens will the corporate culture I've become accustomed to change overnight?
You may also be interested in...
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.
Former Alexion execs and Rallybio co-founders Martin Mackay, Steve Uden and Jeffrey Fryer closed a series B venture capital round to take three candidates into the clinic and acquire additional programs.